To explore the mechanism of Yigong San anti-gastric cancer and immune regulation.
World J Gastrointest Oncol
; 16(5): 1965-1994, 2024 May 15.
Article
em En
| MEDLINE
| ID: mdl-38764819
ABSTRACT
BACKGROUND:
Yigong San (YGS) is a representative prescription for the treatment of digestive disorders, which has been used in clinic for more than 1000 years. However, the mechanism of its anti-gastric cancer and regulate immunity are still remains unclear.AIM:
To explore the mechanism of YGS anti-gastric cancer and immune regulation.METHODS:
Firstly, collect the active ingredients and targets of YGS, and the differentially expressed genes of gastric cancer. Secondly, constructed a protein-protein interaction network between the targets of drugs and diseases, and screened hub genes. Then the clinical relevance, mutation and repair, tumor microenvironment and drug sensitivity of the hub gene were analyzed. Finally, molecular docking was used to verify the binding ability of YGS active ingredient and hub genes.RESULTS:
Firstly, obtained 55 common targets of gastric cancer and YGS. The Kyoto Encyclopedia of Genes and Genomes screened the microtubule-associated protein kinase signaling axis as the key pathway and IL6, EGFR, MMP2, MMP9 and TGFB1 as the hub genes. The 5 hub genes were involved in gastric carcinogenesis, staging, typing and prognosis, and their mutations promote gastric cancer progression. Finally, molecular docking results confirmed that the components of YGS can effectively bind to therapeutic targets.CONCLUSION:
YGS has the effect of anti-gastric cancer and immune regulation.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Idioma:
En
Revista:
World J Gastrointest Oncol
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
China